SWAN Investors are pleased to announce an investment in NexPlasmaGen, a Canadian company that is working to reduce cancer recurrence safely and cost-effectively by developing a cold plasma medical device that targets and destroys residual cancer cells following tumor removal.
The innovation builds on well-understood mechanisms of cancer cell death—namely, oxidative stress—while offering a highly localized, minimally invasive tool to surgeons. By integrating this technology into standard surgical procedures, NexPlasmaGen offers a compelling solution to improve the quality of care and life for patients, especially women undergoing breast-conserving treatments.
As the lead investor, SWAN has helped NexPlasmaGen unlock non-dilutive funding opportunities equivalent to approximately 6.5 times the initial capital invested, primarily in the form of grants. SWAN is proud to support this breakthrough as part of our ongoing commitment to investing in transformative, impact-driven health solutions.